Here, we could suggest that mediating miR-770-5p in combination with trastuzumab treatment could inhibit two important pathways simultaneously, thereby blocking the proliferation, motility and invasion capacities of HER2+ breast cancer cells (S2 Fig). The gene discussed is ERBB2; the disease is breast carcinoma.